Epidemiology and burden of influenza in healthy children aged 6 to 35 months: analysis of data from the placebo arm of a phase III efficacy trial

BMC Infect Dis. 2019 Apr 4;19(1):308. doi: 10.1186/s12879-019-3920-8.

Abstract

Background: Despite World Health Organization recommendations, in many countries young children are not targeted for influenza vaccination. To help inform influenza vaccination policy, we examined the occurrence and burden of influenza in healthy children aged 6 to 35 months using data from a recent phase III placebo-controlled influenza vaccine trial conducted in countries in the Northern and Southern Hemispheres.

Methods: This was an analysis of data from participants included in the placebo arm of a phase III clinical trial in healthy children aged 6 to 35 months (EudraCT no. 2013-001231-51). Included children had never been vaccinated for influenza and were observed for one influenza season. Outcome measures included the occurrence of influenza-like illness (ILI), laboratory-confirmed influenza, virus types/subtypes, severe symptoms and complications of confirmed influenza, and healthcare use associated with confirmed influenza.

Results: Data from 2210 participants were analysed. ILI was reported for 811 participants (36.7%). Of these, 255 participants (31.4%) had 263 virologically confirmed episodes of influenza. The overall influenza attack rate was 11.5%. The most common influenza virus detected was A(H3N2) (40.7%), followed by B/Yamagata (23.6%), A(H1N1) (18.6%), and B/Victoria (8.0%). Grade 3 fever was reported in 24.3% of confirmed episodes, acute lower respiratory infection in 8.7%, acute otitis media in 6.1%, and pneumonia in 1.9%. In most influenza episodes (93.2%), antipyretics, analgesics, or non-steroidal anti-inflammatory drugs were taken. Antibiotics were prescribed for 41.4% of influenza episodes. More than half of the influenza episodes (57.0%) resulted in outpatient visits. Influenza resulted in overnight hospitalisation in 1.1% of episodes.

Conclusions: Influenza is associated with a significant burden of disease in healthy children. This analysis also revealed that antibiotics continue to be frequently used for young children with influenza.

Trial registration: EudraCT no. 2013-001231-51 .

Keywords: Acute lower respiratory infection; Acute otitis media; Antibiotic use; Children; Clinical trial; Epidemiology; Fever; Hospitalisation; Influenza; Pneumonia.

Publication types

  • Clinical Trial, Phase III
  • Multicenter Study
  • Randomized Controlled Trial

MeSH terms

  • Anti-Bacterial Agents / therapeutic use
  • Antipyretics / therapeutic use
  • Child, Preschool
  • Cost of Illness
  • Female
  • Humans
  • Infant
  • Influenza A Virus, H1N1 Subtype / genetics
  • Influenza A Virus, H1N1 Subtype / isolation & purification
  • Influenza A Virus, H3N2 Subtype / genetics
  • Influenza A Virus, H3N2 Subtype / isolation & purification
  • Influenza Vaccines / immunology
  • Influenza, Human / economics
  • Influenza, Human / epidemiology*
  • Influenza, Human / pathology
  • Influenza, Human / virology
  • Male
  • Outcome Assessment, Health Care*
  • Placebo Effect
  • RNA, Viral / genetics
  • RNA, Viral / metabolism
  • Respiratory Tract Infections / diagnosis
  • Respiratory Tract Infections / drug therapy
  • Respiratory Tract Infections / epidemiology
  • Severity of Illness Index

Substances

  • Anti-Bacterial Agents
  • Antipyretics
  • Influenza Vaccines
  • RNA, Viral